Drug Approval | May 05, 2026
Lupin receives USFDA approval for generic Ravicti oral liquid
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Lifts full-year outlook as obesity drug boom accelerates
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
But acquisition charges drag earnings into loss
The transaction marks a clear portfolio reshuffle for Indoco
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Subscribe To Our Newsletter & Stay Updated
